How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,075 results for

physical therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Androgen Therapy in Women Full Text available with Trip Pro

Close mobile search navigation Article navigation 1 October 2014 Article Contents Article Navigation Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline Margaret E. Wierman 1Department of Medicine (M.E.W.), University of Colorado School of Medicine, Aurora, Colorado 800452Veterans Affairs Research Service (M.E.W.), Denver, Colorado 80220 Search for other works by this author on: Wiebke Arlt 3Centre for Endocrinology, Diabetes, and Metabolism (W.A.), School (...) by this author on: Nanette Santoro 10University of Colorado School of Medicine (N.S.), Aurora, Colorado 80045 Search for other works by this author on: The Journal of Clinical Endocrinology & Metabolism , Volume 99, Issue 10, 1 October 2014, Pages 3489–3510, Published: 01 October 2014 Article history Received: 07 May 2014 Accepted: 20 August 2014 Citation Margaret E. Wierman, Wiebke Arlt, Rosemary Basson, Susan R. Davis, Karen K. Miller, Mohammad H. Murad, William Rosner, Nanette Santoro, Androgen Therapy

2014 The Endocrine Society

182. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

of our patients, who risk their well-being as volunteer participants in clinical studies. Met h o d s Th e goal of this CHEST guideline project was to produce clinically relevant and useful recommendations on medical therapies for PAH for clinicians who treat adult patients with PAH. Health-care providers should use these guidelines to assist patients with treatment choices that optimize benefi ts and minimize harms and burdens. In 2011, the Institute of Medicine (IOM) released new guideline (...) It is a critical responsibility of the clinician to ensure that an accurate diagnosis is established, and readers are referred to previously published guidelines by the American College of Chest Physicians (CHEST) and other organizations on the evaluation of PH and diagnosis of PAH. 2 - 4 Th e recom- mendations in this guideline are for the treatment of patients with PAH and should not be applied to the treatment of patients with other types of PH. None of the drugs currently approved for therapy for PAH

2014 American College of Chest Physicians

183. Chemo- and Targeted Therapy for Women with HER2 Negative (or unknown) Advanced Breast Cancer Full Text available with Trip Pro

on by the Expert Panel via consensus. Results Seventy-nine studies met the inclusion criteria, comprising 20 systematic reviews and/or meta-analyses, 30 trials on first-line treatment, and 29 trials on second-line and subsequent treatment. These trials form the evidence base for the guideline recommendations. Recommendations Endocrine therapy is preferable to chemotherapy as first-line treatment for patients with estrogen receptor–positive metastatic breast cancer unless improvement is medically necessary (eg (...) workers, and any other relevant member of a comprehensive multidisciplinary cancer care team) and patients. Methods An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature. Recommendations 1. Endocrine therapy, rather than chemotherapy, should be offered as the standard first-line treatment for patients with hormone receptor–positive advanced/metastatic breast cancer, except for immediately life threatening disease

2014 American Society of Clinical Oncology Guidelines

184. Integrative Therapies During and After Breast Cancer Treatment

, American Society of Clinical Oncology, Alexandria, VA; Ting Bao and Gary E. Deng, Memorial Sloan Kettering Cancer Center; Dawn L. Hershman, Columbia University Medical Center, New York; Karen M. Mustian, University of Rochester Medical Center, Rochester, NY; Angela M. DeMichele, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Judith M. Fouladbakhsh, Oakland University, Rochester, MI; Brigitte Gil, Lahey Hospital and Medical Center, Burlington, MA; Sami Mansfield, Cancer (...) treatment? Target Population Patients undergoing treatment of breast cancer and survivors of breast cancer Target Audience Oncologists, integrative medicine providers, supportive care specialists, nurses, pharmacists, primary care providers, and patients with breast cancer Methods An ASCO Expert Panel was convened to consider endorsing the SIO guideline, Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment. Recommendations in the SIO

2018 American Society of Clinical Oncology Guidelines

185. Practice Guideline Recommendations Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

, and vascular risk factors, and adverse health behaviors (e.g., physical inactivity, smoking) are associated with worse outcomes. 9,10 Addressing depression before initiating DMT may improve decision making and adherence to DMT. Concomitant medications may have important interactions with DMTs. 11 Level B Clinicians should counsel about comorbid disease, adverse health behaviors, and potential interactions of the DMT with concomitant medications when people with MS initiate DMTs.AAN.com ©2018 American (...) of the therapy in people with MS on DMTs. Clinicians should follow up either annually or according to medication-specific REMs in people with MS on DMTs. Starting: Recommendation 11 Rationale DMTs have potential risks in pregnant women 30 to varying degrees. Discussing pregnancy with women with MS before initiating DMT is a part of good clinical practice. If women with MS are planning pregnancy soon, DMT use may need to be deferred until after pregnancy. 31 In addition, because DMTs vary in terms

2018 American Academy of Neurology

186. Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

Academy of Neurology AEs: adverse effects ALT: alanine aminotransferase ARRs: annualized relapse rates AST: aspartate aminotransferase CIS: clinically isolated syndrome CMSC: Consortium of Multiple Sclerosis Centers” COI: conflict of interest CV: curriculum vitae DMTs: disease-modifying therapies EDSS: Expanded Disability Status Scale FDA: US Food and Drug Administration GDDI: Guideline Development, Dissemination, and Implementation Subcommittee IOM: Institute of Medicine mIUs: milli-international (...) by the GDDI before and after the public comment period. Panel members developed the clinical questions and the data extraction template. The guideline panel defined DMTs as medications that aim to affect the clinical course of MS by decreasing relapses or slowing disease progression or both. The guideline panelists limited the search for relevant literature to medications that have been approved by the US Food and Drug Administration (FDA), Health Canada, or the European Medicines Agency

2018 American Academy of Neurology

187. Palliative radiation therapy for bone metastases

Palliative radiation therapy for bone metastases Special Article Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline Stephen Lutz MD a, ? , Tracy Balboni MD MPH b , Joshua Jones MD c , Simon Lo MB ChB d , Joshua Petit MD e , Shayna E. Rich MD PhD f , Rebecca Wong MB ChB g , Carol Hahn MD h a DepartmentofRadiationOncology,EasternWoodsRadiationOncology,15990MedicalDriveSouth,Findlay,Ohio45840 b Department of Radiation Oncology, and Department (...) of Psychosocial Oncology and Palliative Care Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts c Department of Radiation Oncology, University of Pennsylvania Health System, Philadelphia, Pennsylvania d Department of Radiation Oncology, University of Washington Schoolof Medicine, Seattle, Washington e Department of Radiation Oncology, University of Colorado Health, Fort Collins, Colorado f Hospice and Palliative Medicine, Mayo Clinic College of Medicine, Jacksonville, Florida

2016 American Society for Radiation Oncology

188. Prioritizing Functional Capacity as a Principal End Point for Therapies Oriented to Older Adults With Cardiovascular Disease

exacerbate risks of disability, dependency, and frailty. Whereas most major randomized controlled trials of therapies for cardiovascular disease (CVD) are usually oriented to outcomes metrics of mortality, morbidity (clinical events), and hospitalizations, they rarely address the associated risks of functional loss that can occur even if the initial therapies seem to go well. Not only are strategies to better preserve physical capacity and to minimize declines important steps to reduce disease-related (...) relative effort to perform equivalent work for daily tasks. Many individuals then choose to avoid tasks that have become relatively more stressful, with the result that physical activity and CRF become further reduced. Balance and flexibility are also required for many daily activities and decline with age, especially in the context of changing muscle mass and function, neurogenic factors, bone loss, and degenerative changes in connective tissue. Medications further exacerbate these vulnerabilities via

2017 American Heart Association

189. External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer

a 2003 American Association of Physicists in Medicine (AAPM) task group report [136], are that beam arrangements avoid the prosthesis [124,128,129], use more arcs [137], that inhomogeneity corrections be turned off during treatment planning, that dose perturbations be estimated, and that exit doses be measured during EBRT delivery. Additionally, there are special considerations for helical tomotherapy [138] and proton therapy [139-141]. Obesity Obese patients may present a challenge for highly (...) to clinicians. The AAPM task group report to provide guidance on the delivery, treatment planning, and clinical implementation of IMRT in 2003 [217]. AAPM Task Group 101 provides guidance on SBRT planning and delivery, including technical aspects of treatment planning and delivery [221]. The ACR Technical Standard for the Performance of Radiation Oncology Physics for External Beam Therapy provides guidance on the required steps of EBRT planning, QA, and delivery [216]. The ACR-ASTRO Practice Parameters

2016 American College of Radiology

190. Management of Opioid Therapy (OT) for Chronic Pain

clinicians or specialists to study and consider the latest information on opioid therapy (OT) and how and whether to incorporate that information or recommendations into their practice. It can be used to provide specific information to guide a patient encounter, such as looking up the dosing of a medication used less frequently or the meaning of the urine drug testing (UDT) result. The section on tapering and its accompanying appendix can be used to assist in the development of a framework for guiding (...) ui d el i n e f o r O p ioid T h e r a p y for Ch r on ic Pa in February 2017 Page 4 of 198 B. Risk Mitigation 46 51 70 71 75 75 75 80 81 81 88 99 100 105 105 110 116 116 120 122 C. Type, Dose, Duration, Follow-up, and Taper of Opioids D. Opioid Therapy for Acute Pain Appendix A: VA Signature Informed Consent Appendix B: Urine Drug Testing A. Benefits of Urine Drug Testing B. Types of Urine Drug Testing Appendix C: Diagnostic and Statistical Manual of Mental Disorders for Opioid Use Disorders

2017 VA/DoD Clinical Practice Guidelines

191. Hormone Therapy in Primary Ovarian Insufficiency

Hormone Therapy in Primary Ovarian Insufficiency Hormone Therapy in Primary Ovarian Insufficiency - ACOG Menu ▼ Hormone Therapy in Primary Ovarian Insufficiency Page Navigation ▼ Number 698, May 2017 Committee on Gynecologic Practice This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice in collaboration with committee member Samantha F. Butts, MD, MSCE. This document reflects emerging clinical and scientific advances (...) as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Hormone Therapy in Primary Ovarian Insufficiency ABSTRACT: Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency

2017 American College of Obstetricians and Gynecologists

192. Antenatal Corticosteroid Therapy for Fetal Maturation

Antenatal Corticosteroid Therapy for Fetal Maturation Antenatal Corticosteroid Therapy for Fetal Maturation - ACOG Menu ▼ Antenatal Corticosteroid Therapy for Fetal Maturation Page Navigation ▼ INTERIM UPDATE A correction was published in November 2017 for this title. Click to view the correction. Number 713, August 2017 (Replaces Committee Opinion No. 677, October 2016) (Reaffirmed 2018) Committee on Obstetric Practice This Committee Opinion was developed by the American College (...) of Obstetricians and Gynecologists’ Committee on Obstetric Practice in collaboration with committee members Yasser Y. El-Sayed, MD, Ann E.B. Borders, MD, MSc, MPH, and the Society for Maternal–Fetal Medicine’s liaison member Cynthia Gyamfi-Bannerman, MD, MSc. This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods

2017 American College of Obstetricians and Gynecologists

193. Lower Extremity Arterial Revascularization?Post-Therapy Imaging

(TcPO2). a Research Author, University of Michigan Health System, Ann Arbor, Michigan. b Principal Author and Panel Vice-chair, University of Michigan Health System, Ann Arbor, Michigan. c Panel Chair, UT Southwestern Medical Center, Dallas, Texas. d Scripps Green Hospital, La Jolla, California; Society for Vascular Surgery. e Northwestern Medicine, Chicago, Illinois. f University of Wisconsin, Madison, Wisconsin. g Massachusetts General Hospital, Boston, Massachusetts. h Cleveland Clinic Heart (...) Revascularization Variant 3: Previous infrainguinal endovascular therapy or bypass, presenting with cold, painful extremity and diminished pulses (acute limb ischemia). Initial imaging. Physical examination is critical in suspected acute limb ischemia/threatened limb, which is, at its core, a clinical diagnosis. The temperature and appearance of the limb, absence of palpable pulses or arterial signals by Doppler, loss of sensation, and decreased or absent strength in the affected extremity all provide insight

2017 American College of Radiology

194. Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer

, Alberti G, Bisagni G, Botti E, Peracchia G. Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat. 1984;4(4):309-313. 6. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830-849. 7. Bosch AM, Kessels AG, Beets GL, et al. Preoperative estimation of the pathological breast tumour size by physical examination (...) Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer New 2017 ACR Appropriateness Criteria ® 1 Monitoring Response to Neoadjuvant Chemotherapy American College of Radiology ACR Appropriateness Criteria ® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer Variant 1: Initial determination of tumor size and extent within the breast prior to neoadjuvant chemotherapy. Initial imaging examination. Radiologic Procedure Rating Comments RRL* Mammography diagnostic 9

2017 American College of Radiology

195. The 2017 hormone therapy position statement of The North American Menopause Society

symptoms not relieved with over-the-counter therapiesandwithoutindicationsforuseofsystemicHT,low-dosevaginalestrogentherapyorothertherapiesarerecommended. Key Words: Breast cancer – Cardiovascular disease – Cognition – Estrogen – Hormone therapy – Menopause – Position Statement – Vaginal atrophy – Vasomotor symptoms This NAMS position statement has been endorsed by Academy of Women’s Health, American Association of Clinical Endocrinologists, American Association of Nurse Practitioners, American Medical (...) and transdermal progesterone is poor. Micronized progesterone needs to be adequately dosed for endometrial protection. 17-19 Improperly formulated or FIG. 1. Absolute risks of health outcomes by 10-year age groups in the Women’s Health Initiative Hormone Therapy Trials during the intervention phase. CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate. From Manson et al. 14 Reproduced with permission of the American Medical Association American Medical Association. All rights reserved. NAMS

2017 The North American Menopause Society

196. Implementation of Supervised Exercise Therapy for Patients With Symptomatic Peripheral Artery Disease: A Science Advisory From the American Heart Association Full Text available with Trip Pro

such as a clinical exercise professional are advisable. During these contacts, patients should be helped to set exercise goals and to self-monitor progress, and challenges, including strategies to overcome barriers to exercise, should be discussed. Conclusions Exercise is the most effective medical therapy for improving walking ability and preventing mobility disability in patients with PAD. The evidence supporting SET is extensive and robust. The 2017 decision memorandum from CMS to cover SET for patients (...) A. Creager Dartmouth-Hitchcock Medical Center Heart and Vascular Center AHA (Strategically Focused Vascular Disease Research Network, unpaid) None None None None None None Jonathan K. Ehrman Henry Ford Health System None None None None None None None Andrew W. Gardner Penn State Hershey College of Medicine None None None None None None None Ryan J. Mays University of Minnesota None None None None None None None Judith G. Regensteiner University of Colorado Denver School of Medicine Center for Women’s

2019 American Heart Association

197. Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

for management of acute intermediate- and high-risk PE is rapidly evolving. Two interventional devices using pharmacomechanical means to recanalize the pulmonary arteries have recently been cleared by the US Food and Drug Administration for marketing, and several others are in various stages of development. The purpose of this document is to clarify the current state of endovascular interventional therapy for acute PE and to provide considerations for evidence development for new devices that will define (...) interventional PE therapies. Figure 2. Flowtriever catheter-based embolectomy device. Used with permission of Inari Medical, Irvine CA. Summary Current interventional therapies for acute PE include devices that facilitate CDL or catheter-based embolectomy. Two interventional devices, the EKOSonic endovascular system and the FlowTriever embolectomy device, have been cleared by the FDA for use in acute PE, with other devices pursuing clearance. Rationale for Interventional Therapies for Acute PE The rationale

2019 American Heart Association

198. Insulin therapy in type 1 diabetes

complications (diabetic ketoacidosis and dyslipidaemia). In people with type 1 diabetes, autoimmune destruction of pancreatic beta-cells results in absolute insulin deficiency. Consequently, insulin therapy is a medical necessity. Three types of insulin are available in the UK: human insulins, human insulin analogues, and animal insulins (rarely used). Insulins are broadly categorized according to their time-action profiles as: Short-acting insulins — these are used to mimic the physiological secretion (...) ; however, the advice for driving has been changed in line with the updated Driver and Vehicle Licensing Agency (DVLA) guidance for people with diabetes mellitus. The topic has been restructured, and the scope has been clearly defined. August 2014 — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a medical device alert stating that Accu-Chek Compact®, Accu-Chek Mobile®, and Accu-Chek Active® devices and test strips may give falsely low blood glucose readings

2016 NICE Clinical Knowledge Summaries

199. Insulin therapy in type 2 diabetes

and management (2015) [ ]. Previous changes Previous changes August 2014 — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a medical device alert stating that Accu-Chek Compact ® , Accu-Chek Mobile ® , and Accu-Chek Active ® devices and test strips may give falsely low blood glucose readings in people receiving ceftriaxone therapy. July 2013 — minor update. Links to the DVLA website have been updated. March 2013 — minor update. The telephone number for NHS Direct has (...) complications (dyslipidaemia and diabetic ketoacidosis). In people with type 2 diabetes, there is a variable combination of increased insulin resistance and progressive loss of pancreatic beta-cell function. Type 2 diabetes is initially managed with lifestyle changes and antidiabetic drugs. However, with time, many people will require insulin therapy as there is insufficient endogenous insulin to maintain adequate glucose control. Three types of insulin are available in the UK: human insulins, human insulin

2016 NICE Clinical Knowledge Summaries

200. Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer

In general, the six RCTs included in this review were of high quality (See Appendix 1). None of the five trials that reported the source of funding was funded by pharmaceutical companies (5,6,20,28,31). Adequate randomization methods were described in five trials (5,6,20,28,31) and were not reported in one trial (29). Sauer et al (31) reported significantly more patients with tumours 5 cm or less from the anal verge in the preoperative therapy group compared with the postoperative therapy group (...) Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer Evidence-Based Series 2-4 Version 3 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer Members of the Gastrointestinal Cancer Disease Site Group Evidence-based Series (EBS) 2-4 Version 3 was reviewed in 2019 and ENDORSED by the Gastrointestinal

2019 Cancer Care Ontario

Guidelines

Guidelines – filter by country